- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06752356
Une étude portant sur l'immunoglobuline normale humaine (IGIV) par voie intraveineuse à 10 % chez des sujets atteints de polyneuropathie démyélinisante inflammatoire chronique (PIDC)
Une étude multicentrique en double aveugle, randomisée, évaluant l'efficacité et l'innocuité de deux doses différentes d'immunoglobuline normale humaine (IGIV) intraveineuse à 10 % chez des sujets atteints de polyneuropathie démyélinisante inflammatoire chronique (PIDC)
The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a Double Blind, Randomized study. All subjects will enter a wash-out phase of up to 12 weeks, or until functional deterioration, defined as an increase of ≥1 point (worsening) in the adjusted INCAT disability score, is demonstrated. Eligible subjects will then be randomized in a 1:2 ratio to receive either 0.5 g/kg or 1.0 g/kg KIg10 at 3-weekly intervals for 21 weeks. Subjects who relapse during randomized treatment due to functional deterioration, based on the INCAT score, will be rescued with 2.0 g/kg KIg10 at 3-weekly intervals for 21 weeks.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Anna Lotti Suffredini
- Numéro de téléphone: +39 338 6827568
- E-mail: a.lotti@kedrion.com
Sauvegarde des contacts de l'étude
- Nom: Esra Cinar-Jones
- Numéro de téléphone: +44 7551 563340
- E-mail: e.cinarjones@kedrion.com
Lieux d'étude
-
-
Connecticut
-
Stamford, Connecticut, États-Unis, 06905
- Recrutement
- New England Institute for Clinical Research
-
Chercheur principal:
- Peter McAllister
-
-
Florida
-
Miami, Florida, États-Unis, 33155
- Recrutement
- Quantix Research
-
Chercheur principal:
- Sergio Jaramillo
-
Pembroke Pines, Florida, États-Unis, 33024
- Recrutement
- Best Choice Medical and Research Service
-
Chercheur principal:
- Vaniolky Losada Leon
-
Tampa, Florida, États-Unis, 33613
- Recrutement
- USF Health - Morsani Center for Advanced Healthcare
-
Chercheur principal:
- Kathleen Murray
-
-
New Hampshire
-
Lebanon, New Hampshire, États-Unis, 03756
- Recrutement
- Dartmouth-Hitchcock Medical Center
-
Chercheur principal:
- Victoria Lawson
-
-
Texas
-
El Paso, Texas, États-Unis, 79912
- Recrutement
- Advanced Neurology Epilepsy and Sleep Center/ANESC Research
-
Chercheur principal:
- Aamr Herekar
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Male or female, aged ≥18 years.
-
Written informed consent and authorization to access personal health information obtained independently from participants indicating that they understand the purpose of, and procedures required for, the study and are willing to participate.
-
Documented diagnosis of CIDP consistent with the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria.
-
Current or documented history of significant disability, as defined by an overall INCAT disability score between 2 and 9. A score of 2 must be exclusively from the lower extremities.
-
Participants are currently dependent on treatment with immunoglobulins, corticosteroids, or standard of care treatments for CIDP.
-
Weakness of at least two limbs.
-
Participants should be clinically stable 12 weeks prior to screening date as defined by:
- without a worsening in INCAT score of ≥1 point, AND/OR without significant changes in clinical symptoms AND
- without significant dose changes or requiring additional treatments.
Exclusion Criteria:
-
Patients' incapable of giving informed consent.
-
Pure sensory and other CIDP variants.
-
Females who are pregnant, breastfeeding, unwilling to practice effective birth control methods as defined in Appendix C throughout the study, or planning a pregnancy during the study.
-
IG-experienced participants requiring an IGIV dosage of more than 1.4 g/kg/month OR SCIG pre-treated participants requiring a SCIG dosage of more than 1.6 g/kg/month.
-
Participants who have previously failed to respond to IGIV or SCIG.
-
On screening date, a body mass index (BMI) > 35 kg/m2 or an IGIV dose that puts the patient at risk of fluid overload.
-
CIDP and any neuropathy of other causes not consistent with the 2021 EAN/PNS criteria including:
- Hereditary demyelinating neuropathies, such as a hereditary sensory and motor neuropathy (HSMN) (Charcot-Marie-Tooth [CMT] disease), and hereditary sensory and autonomic neuropathies (HSANs).
- Neuropathies secondary to infections, disorders, or systemic diseases such as Borrelia burgdorferi infection (Lyme disease), diphtheria, systemic lupus erythematosus, POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexopathy or neuropathy, lymphoma, and amyloidosis.
- Multifocal motor neuropathy (MMN).
- Drug-, biologic-, chemotherapy-, or toxin-induced peripheral neuropathy. Peripheral neuropathy induced by vitamin B12 deficiency.
-
Immunoglobulin M (IgM) paraproteinemia, including IgM monoclonal gammopathy with increased titers of antibodies to myelin-associated glycoprotein.
-
Central demyelinating disorders (e.g, multiple sclerosis) or severe myopathy.
-
Any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or may interfere with assessment of CIDP or outcome measures (e.g., severe arthritis, stroke, Parkinson's disease, and diabetic peripheral neuropathy) [participants with clinically diagnosed diabetes mellitus, who have adequate glycemic control with Hemoglobin A1C (HbA1C) of <7.5% at screening, and who agree to maintain adequate glycemic control during the study are allowed].
-
Congestive heart failure (New York Heart Association (NYHA) Class III/IV), unstable angina, unstable cardiac arrhythmias, or uncontrolled hypertension [i.e., diastolic blood pressure >100 mmHg and/or systolic blood pressure >160 mmHg]. If a single measure exceeds this limit, a triple repeat measurement may be performed and the average of the three measurements used.
-
History of deep vein thrombosis or thromboembolic events (e.g, cerebrovascular accident, pulmonary embolism) in the past 12 months.
-
Condition(s) which could alter protein catabolism and/or IgG utilization (e.g, protein-losing enteropathies, nephrotic syndrome).
-
Known history of chronic kidney disease, or glomerular filtration rate (GFR) of <60 milliliter per minute per 1.73 square meter (mL/min/1.73m2) estimated based on an established chronic kidney disease epidemiology collaboration (CKD-EPI) equation at the time of screening.
-
Active malignancy requiring chemotherapy and/or radiotherapy, or history of malignancy with less than 2 years of complete remission prior to screening. Exceptions are adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment.
-
Hypersensitivity or adverse reactions (e.g, urticaria, breathing difficulty, severe hypotension, or anaphylaxis) to human blood products such as human IgG, albumin, or other blood components.
-
Known history of immunoglobulin A (IgA) deficiency.
-
Known history of autoimmune nodo-paranodopathies causing IG treatment resistance, including anti-neurofascin (NF) 186 antibodies and antibodies against paranodal proteins, such as NF155, contactin 1 (CNTN1), and contactin-associated protein 1 (CASPR1).
-
Abnormal laboratory values at screening:
- Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5x upper limit of normal (ULN)
- Platelet count <100,000 cells/µL.
- Absolute neutrophil count (ANC) <1000 cells/µL.
- Clinically significant anemia or hemoglobin (Hgb) level of < 10.0 g/dL at screening.
-
Ongoing/active infection with hepatitis B virus (HBV), hepatitis C virus (HCV) or HIV Type 1/2 infection. Participants with chronic hepatitis B or hepatitis C infection currently on treatment may participate if they have undetectable viral load within 12 months of screening date.
-
Subjects who have received:
-
Within 2 months before wash-out phase:
- PE
- change in treatment of methotrexate, azathioprine, or mycophenolate
-
Within 3 months before wash-out phase: Efgartigimod alfa (Vyvgart)
-
Within 5 months before wash-out phase: cyclophosphamide, interferon, tumor necrosis factor-alpha inhibitors, fingolimod, or any other immunosuppressive medications
-
Within 12 months before wash-out phase: rituximab or alemtuzumab
-
-
Participants who have received a hematopoietic stem cell transplant.
-
Participants on corticosteroids for the treatment of CIDP after being fully washed out. Participants on maintenance doses of corticosteroid may be allowed, if treatment is for conditions unrelated to CIDP (doses usually below 20 mg/day prednisone or equivalent and where the dosage is unlikely to be tapered during the duration of the trial may be allowed for indications other than CIDP).
-
Any disorder or condition that in the investigator's judgment may impede the participant's participation in the study, pose increased risk to the participant, or confound the results of the study.
-
Participation in another clinical study involving an investigational medicinal product (IMP) or investigational device within 30 days prior to screening visit or within 5 half-lives of the IMP under investigation or is scheduled to participate in another clinical study involving an IMP or investigational device during the intended course of this study.
-
History of acquired or inherited thrombophilic disorders. These will include the specific types of acquired or inherited thrombophilic disorders that could put participants at risk of developing thrombotic events. Examples include, but are not restricted to:
-
Hereditary thrombophilia, examples include
- Factor V Leiden mutation.
- Prothrombin 20210A mutation.
- Protein C deficiency.
- Protein S deficiency.
- Antithrombin deficiency.
-
Acquired thrombophilias, examples include:
- Antiphospholipid antibody syndrome.
- Activated protein C Resistance acquired.
- Homocysteinemia.
-
-
Previous participation in this clinical study, except for participants who withdrew consent during the washout phase, prior to randomization.
-
Any other factor that, in the opinion of the investigator, would prevent the subject from complying with the requirements of the protocol.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: 1.0 g/kg dose group for 24 weeks
This group will receive, initial loading dose of 2.0 g/kg of Intravenous (IV) KIg10 (Immunoglobulin) infusion followed by 1.0 g/kg of IV KIg10 every 3 weeks. |
Kedrion intravenous immunoglobulin (IVIg) 10%
Autres noms:
|
|
Expérimental: 0.5 g/kg dose group for 24 weeks
This group will receive, Initial loading dose of 2.0 g/kg of Intravenous (IV) KIg10 (Immunoglobulin) infusion will be given followed by 0.5 g/kg of IV KIg10 every 3 weeks. |
Kedrion intravenous immunoglobulin (IVIg) 10%
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Efficacy of 1.0 g/kg KIg10 in the treatment of adult subjects with active CIDP
Délai: From Baseline upto 24 weeks of treatment
|
The proportion of responders in the 1.0 g/kg KIg10 arm, at week 24 relative to Randomization Baseline week 0, based on the adjusted INCAT disability score. A responder is defined as having a ≥1 point decrease (improvement) in the adjusted INCAT score at week 24 relative to adjusted INCAT score at randomization baseline. |
From Baseline upto 24 weeks of treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Efficacy of 0.5 g/kg KIg10 in the treatment of adult subjects with active CIDP
Délai: From Baseline upto 24 weeks of treatment
|
The proportion of responders in the 0.5 g/kg KIg10 arm at week 24 relative to randomization baseline, based on the adjusted INCAT disability score. A responder is defined as having a ≥1 point decrease (improvement) in the adjusted INCAT score at week 24 relative to adjusted INCAT score at randomization baseline. |
From Baseline upto 24 weeks of treatment
|
|
Proportion of responders (Week 24 vs Baseline) in both dose groups
Délai: From Baseline upto 24 weeks of treatment
|
Proportion of responders in both dose groups based on Grip Strength and I-RODs |
From Baseline upto 24 weeks of treatment
|
|
Proportion of responders in rescued subjects
Délai: End of Treatment vs onset of rescue treatment
|
Proportion of responders in rescued subjects based on grip strength, I-RODS scores, adjusted INCAT disability score |
End of Treatment vs onset of rescue treatment
|
|
Improvers based on the MRC-sumscore
Délai: From Baseline upto 24 weeks of treatment
|
Improvers by a change of 4 points in both dose groups (week 24 versus baseline) based on MRC-sumscore |
From Baseline upto 24 weeks of treatment
|
|
Mean Change in MRC-sumscore
Délai: From Baseline upto 24 weeks of treatment
|
Mean change in MRC-sumscore for both dose groups at week 24 vs baseline |
From Baseline upto 24 weeks of treatment
|
|
Mean Change in MRC-sumscore for rescued subjects
Délai: End of Treatment vs onset of rescue treatment
|
Mean change in MRC-sumscore for rescued subjects from End of Treatment versus onset of rescue treatment |
End of Treatment vs onset of rescue treatment
|
|
Disease Related QoL (CAPPRI) for each dose level
Délai: From Baseline upto 24 weeks of treatment
|
For each dose level the Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) will be analysed for disease related QoL |
From Baseline upto 24 weeks of treatment
|
|
Mean change in I-RODS
Délai: From Baseline upto 24 weeks of treatment
|
For each dose level, mean change from randomization baseline (visit 2, week 0) to end of study (visit 10, week 24) in Inflammatory-Rasch-built Overall Disability Scale (I- RODS) score |
From Baseline upto 24 weeks of treatment
|
|
Mean change in I-RODS for rescued subjects
Délai: End of Treatment vs onset of rescue treatment
|
Mean change to the end of treatment assessments prior to onset of rescue treatment, in Inflammatory-Rasch-built Overall Disability Scale (I- RODS) score for rescued subjects |
End of Treatment vs onset of rescue treatment
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of adverse events
Délai: From Baseline upto 25 weeks
|
Assess Safety and Tolerability of KIg10 |
From Baseline upto 25 weeks
|
|
The proportion of patients experiencing at least one adverse event.
Délai: From Baseline upto 25 weeks
|
Assess Safety and Tolerability of KIg10 |
From Baseline upto 25 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Lakshmi Deshpande, Kedrion S.p.A.
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système nerveux
- Processus pathologiques
- Maladies neuromusculaires
- Maladie chronique
- Attributs de la maladie
- Maladies auto-immunes
- Maladies du système immunitaire
- Maladies du système nerveux périphérique
- Maladies auto-immunes du système nerveux
- Maladies démyélinisantes
- Polyneuropathies
- Polyradiculonévrite
- Conditions pathologiques, signes et symptômes
- Polyradiculonévrite Chronique Inflammatoire Démyélinisante
- Acides aminés, peptides et protéines
- Protéines
- Préparations pharmaceutiques
- Thérapeutique
- Voies d'administration du médicament
- Pharmacothérapie
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Immunoglobulines
- Administration, intraveineuse
- Solutions
Autres numéros d'identification d'étude
- KB071
- KB071 (Autre identifiant: Kedrion S.p.A)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Publishing of data and IPD that underlie results in the publication will be determined at study completion to comply with ICJME minimum requirements.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .